Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Viking2233on Nov 04, 2023 3:04pm

190 Views

Post# 35717608

Turkish Approval

It has been about 5 weeks since we submitted our application to start Phase 2 AKI trial to Turkish Ministry of Health. The fact we have history with doing previous phase 2 in Turkey, I anticipate news soon with approval then shortly after 1st dosing. It would not surprise me that dosing will ramp. The company has all the required funding in place, they have drug supply manufactured and ready to go.

I believe we are close to seeing the algorithm trading reversing here and we could see share price escalation by end of year.

Good luck to all long investors.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec